CorMatrix® Cardiovascular, Inc. is a privately held medical device company dedicated to developing and delivering innovative biomaterial devices that harness the body’s innate ability to repair damaged cardiac and vascular tissue
CorMatrix ECM Technology allows surgeons to restore the native anatomy of cardiac and vascular tissue in need of repair, serving as a superior alternative to synthetic or cross-linked materials. CorMatrix is an innovative implantable medical device that enables migration, vascularization, and remodeling of pericardial, cardiac and venous tissues. The patient’s native tissue is restored with no foreign materials left behind to cause scarring or adhesions.
Research on extracellular matrix materials began in the 1980’s. Prior to then, it was believed that extracellular matrix in humans served little function. As research in regenerative medicine advanced, scientists zeroed in on extracellular matrix and its key role in supporting and promoting new tissue growth. Realizing the potential of these unique materials, CorMatrix was founded to further develop ECM biomaterials into viable medical devices. In 2005, CorMatrix received its first FDA clearance and shifted its focus from development to a fully integrated commercial entity.
Today, the Company continues to research, develop and deliver products using extracellular matrix for a variety of cardiac, vascular and other indications. CorMatrix products have U.S. clearance and European CE mark. Since its launch in 2006, CorMatrix has been used at more than 1000 hospitals across the U.S. and implanted in over 145,000 cardiac and vascular procedures.